Velpatasvir-d₃  (Synonyms: GS-5816-d3₃)

Velpatasvir-d₃ (GS-5816-d₃) is deuterium labeled Velpatasvir. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL^pro inhibitor with an IC₅₀ of 2.16 μM^[1][2][3].

886.02

C₄₉H₅₁D₃N₈O₈

1377049-84-7

O=C(OC)N[C@@H](C(C)C)C(N1[C@@H](C2=NC3=CC=C4C=C5C(OCC6=C5C=CC(C7=CNC([C@H]8N(C([C@H](NC(OC([2H])([2H])[2H])=O)C9=CC=CC=C9)=O)C[C@@H](COC)C8)=N7)=C6)=CC4=C3N2)CC[C@@H]1C)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.  [Content Brief]

  [2]. Yasmeen S, et al. An insight into the hepatoprotective role of Velpatasvir and Sofosbuvir per se and in combination against carbon tetrachloride-induced hepatic fibrosis in rats. Environ Sci Pollut Res Int. 2023 Sep;30(42):95660-95672.  [Content Brief]

  [3]. Lawitz EJ et al. Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein. Antimicrob Agents Chemother. 2016 Aug 22;60(9):5368-78.  [Content Brief]

  [4]. Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212.  [Content Brief]